header-sticker
header-sticker-mobile

Plasma-free C1-INH acute treatment from day 1

Onset of HAE attacks typically occurs during childhood or adolescence**.

In paediatric HAE patients, one dose*** of RUCONEST®

0%

Successfully treated 96% of HAE attacks in children aged 5 to 14 years10

n=20 (70 of a total of 73 attacks) 

0%

Raised C1-INH levels back to normal**** in 90% of children aged 5 to 14 years7

n=20 (18 of a total of 20 patients)

0%

Raises C1-INH levels back to normal**** in 91% of children aged 2 to <5 years7

As shown on a population PK model.

Recombinant design4

Safety
no risk of human
blood-borne viruses4

No reported
C1-INH inhibitors10

99% purity5,6

* RUCONEST® is indicated for treatment of acute angioedema attacks in adults, adolescents, and children (aged 2 years and above) with hereditary angioedema (HAE) due to C1 esterase inhibitor deficiency.
** Mean age of symptom onset in HAE patients: 4‐14 years.10
*** Dosing of RUCONEST® is body weight dependent and one dose is, therefore, based on patient weight as follows; <42kg = up to 1 vial, 42-84 kg = 50 U/kg (up to 2 vials), >84kg = 2 vials. In children an additional dose may be administered if the patient has not responded adequately after 60 minutes.
**** Above the lower limit of the normal range as observed in healthy individuals(0.7-1.3 U/ml).4
○ No evidence of C1‐INH neutralizing antibodies (inhibitors) has been observed in children aged 5 to 14 years treated with rhC1‐INH.10
‡ Figure is rounded based upon 98.6% (Feussner6) and 98.7% (van Veen5); there are virtually no host related impurities.